Vitamin D Supplementation and Glycemic Outcomes
Insulin Resistance
About this trial
This is an interventional prevention trial for Insulin Resistance focused on measuring Vitamin D, Glucose, HbA1C, Insulin resistance, Blood lipids
Eligibility Criteria
Inclusion Criteria:
- Participants with no medical history of congestive heart failure, acute heart insufficiency and renal failure were included
Exclusion Criteria:
- Participants with medical history of congestive heart failure, acute heart insufficiency and renal failure were excluded
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Other
Other
Other
Other
normal-weight adult subjects
overweight adult subjects
normal-weight elderly
overweight elderly
normal-weight adult subjects (n=30, age ≤ 65 years and BMI ≤ 25 kg/m²) All assigned patients received a supplement of 10,000 IU cholecalciferol (Euro-Pharm International, Canada) to be taken three times per week. The treatment was led for a period of 6 months.
overweight adult subjects (n=30, age ≤ 65 years and BMI ≥ 25 kg/m²) All assigned patients received a supplement of 10,000 IU cholecalciferol (Euro-Pharm International, Canada) to be taken three times per week. The treatment was led for a period of 6 months.
normal-weight elderly (n=60, age ≥ 65 years and BMI ≤ 25 kg/m²) All assigned patients received a supplement of 10,000 IU cholecalciferol (Euro-Pharm International, Canada) to be taken three times per week. The treatment was led for a period of 6 months.
overweight elderly (n=60, age ≥ 65 years and BMI ≥ 25 kg/m²) All assigned patients received a supplement of 10,000 IU cholecalciferol (Euro-Pharm International, Canada) to be taken three times per week. The treatment was led for a period of 6 months.